Eli Lilly and Company $LLY Shares Purchased by Community Trust & Investment Co.

Key Points

• Community Trust & Investment Co. has increased its stake in Eli Lilly and Company by 35.3%, now holding 23,589 shares valued at approximately $18.39 million.
• Eli Lilly reported a quarterly EPS of $6.31, exceeding estimates, with significant revenue growth of 37.6% year-over-year.
• The company recently declared a quarterly dividend of $1.50 per share, representing an annualized dividend yield of 0.8%.

Community Trust & Investment Co. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 35.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,589 shares of the company's stock after buying an additional 6,151 shares during the quarter. Community Trust & Investment Co.'s holdings in Eli Lilly and Company were worth $18,388,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. WestEnd Advisors LLC lifted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company in the first quarter worth $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $43,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald acquired 1,565 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on LLY shares. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their target price for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Stock Up 0.9%

Shares of NYSE LLY traded up $7.08 on Monday, reaching $759.07. 1,113,115 shares of the company's stock traded hands, compared to its average volume of 4,089,333. The business's 50 day simple moving average is $738.37 and its two-hundred day simple moving average is $769.80. The company has a market cap of $718.43 billion, a price-to-earnings ratio of 49.60, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.30. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.